Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
Phone+1-614-7937500
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) posted its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter. The biopharmaceutical company had revenue of $0.12 million for the quarter. View Navidea Biopharmaceuticals' Earnings History.
When is Navidea Biopharmaceuticals' next earnings date?
Has Navidea Biopharmaceuticals been receiving favorable news coverage?
Media headlines about NAVB stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Navidea Biopharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totalling 9,005,539 shares, an increase of 0.3% from the February 15th total of 8,979,138 shares. Based on an average daily trading volume, of 392,519 shares, the days-to-cover ratio is presently 22.9 days. Currently, 5.9% of the company's stock are sold short. View Navidea Biopharmaceuticals' Current Options Chain.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Medicure (MPH), Promis Neurosciences (PMN), Bionomics (BNO), CEL-SCI (CVM), Botanix Pharmaceuticals (BOT), 4d Pharma (DDDD), IntelGenx Technologies (IGX), Orgenesis (ORGS), Tissue Regenix Group (TRX), Ergomed (ERGO), Protalix Biotherapeutics (PLX), Ampio Pharmaceuticals (AMPE), Imugene (IMU), OptiBiotix Health (OPTI) and Pediapharm (PDP).
What other stocks do shareholders of Navidea Biopharmaceuticals own?
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Mr. Jed A. Latkin, CEO, COO, CFO, Sec., Treasurer & Director (Age 45)
- Mr. William J. Regan, Chief Compliance Officer (Age 67)
- Ms. Sharon Correia, Sr. Director of Corp. Communications
- Dr. Michael Stanley Rosol Ph.D., Chief Medical Officer
How do I buy shares of Navidea Biopharmaceuticals?
Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of NAVB stock can currently be purchased for approximately $0.14.
How big of a company is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has a market capitalization of $28.10 million.
What is Navidea Biopharmaceuticals' official website?
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NYSEAMERICAN NAVB)
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
